

Resource Summary Report

Generated by [RRID](#) on Jul 31, 2026

HO-8910

RRID:CVCL_6868

Type: Cell Line

Proper Citation

RRID:CVCL_6868

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_6868

Proper Citation: RRID:CVCL_6868

Description: Cell line HO-8910 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Human papillomavirus-related endocervical adenocarcinoma

Defining Citation: [PMID:8082435](#), [PMID:11930655](#), [PMID:25502083](#), [PMID:26116706](#)

Comments: Miscellaneous: Formerly the CCRID database had 2 entries describing this cell line (3111C0001CCC000280, 3131C0001000700024). They were one of the sources for the STR profile of this entry., Population: African American., Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=26116706; CCRID). Originally thought to originate from the ascites of a 51 year old female patient with ovarian serous cystadenocarcinoma..

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HO-8910

Synonyms: Ho-8910, HO8910, Ho8910

Cross References: BTO:BTO_0005438, Wikidata:Q38151529

ID: CVCL_6868

Hierarchy: cvcl_0030

Record Creation Time: 20220427T220439+0000

Record Last Update: 20260725T234259+0000

Ratings and Alerts

No rating or validation information has been found for HO-8910.

Warning: Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=26116706; CCRID). Originally thought to originate from the ascites of a 51 year old female patient with ovarian serous cystadenocarcinoma.

Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00606.

Miscellaneous: Formerly the CCRID database had 2 entries describing this cell line (3111C0001CCC000280, 3131C0001000700024). They were one of the sources for the STR profile of this entry., Population: African American., Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed=26116706; CCRID). Originally thought to originate from the ascites of a 51 year old female patient with ovarian serous cystadenocarcinoma..

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Gong X, et al. (2025) M6A modification mediates CACNA1A stability to drive the progression of ovarian cancer by inhibiting ferroptosis. Journal of ovarian research, 19(1), 4.

Ma J, et al. (2025) Machine learning-based development of a cytotoxicity prediction model for NK cell therapy in cancers. Cellular oncology (Dordrecht, Netherlands), 48(6), 1837.

Wu H, et al. (2024) RPL35A drives ovarian cancer progression by promoting the binding of YY1 to CTCF promoter. Journal of cellular and molecular medicine, 28(6), e18115.

Chen M, et al. (2021) Anti-Tumor Activity of Expanded PBMC-Derived NK Cells by Feeder-Free Protocol in Ovarian Cancer. Cancers, 13(22).

Wang X, et al. (2020) Peptidome characterization of ovarian cancer serum and the identification of tumor suppressive peptide ZYX36-58. Annals of translational medicine, 8(15), 925.

Fan S, et al. (2018) High expression of glutamate-ammonia ligase is associated with unfavorable prognosis in patients with ovarian cancer. Journal of cellular biochemistry, 119(7), 6008.